CRIS Curis Inc.

1.84
+0.05  (+3%)
Previous Close 1.79
Open 1.79
Price To Book -2.36
Market Cap 61,093,283
Shares 33,202,871
Volume 183,339
Short Ratio
Av. Daily Volume 203,555
Stock charts supplied by TradingView

NewsSee all news

  1. Curis to Present at 31st Annual Piper Jaffray Healthcare Conference

    LEXINGTON, Mass., Nov. 26, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer,

  2. Curis Abstracts for Fimepinostat and CA-4948 Accepted for Presentation at the 61st Annual Meeting of the American Society of Hematology

    LEXINGTON, Mass., Nov. 6, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that abstracts for both

  3. Curis Reports Third Quarter 2019 Financial Results

    LEXINGTON, Mass., Nov. 5, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial

  4. Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., Oct. 4, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 1,

  5. Curis to Present at Cantor Fitzgerald Global Healthcare Conference

    LEXINGTON, Mass., Sept. 26, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 update due later at ASH December 9, 2019, 6:00 p.m.
CA-4948
Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 data to be presented at SITC 2019. However, further enrolment is not planned due to insufficient efficacy.
CA170
Solid Tumors and Lymphomas
Approved January 30, 2012.
Vismodegib
Basal Cell Carcinoma
Phase 1 safety data due at ASH December 2019.
Fimepinostat (CUDC-907) and venetoclax
Diffuse-large B-cell lymphoma (DLBCL)

Latest News

  1. Curis to Present at 31st Annual Piper Jaffray Healthcare Conference

    LEXINGTON, Mass., Nov. 26, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer,

  2. Curis Abstracts for Fimepinostat and CA-4948 Accepted for Presentation at the 61st Annual Meeting of the American Society of Hematology

    LEXINGTON, Mass., Nov. 6, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that abstracts for both

  3. Curis Reports Third Quarter 2019 Financial Results

    LEXINGTON, Mass., Nov. 5, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial

  4. Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., Oct. 4, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 1,

  5. Curis to Present at Cantor Fitzgerald Global Healthcare Conference

    LEXINGTON, Mass., Sept. 26, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer,

  6. Curis Announces Promotion of Bill Steinkrauss to Chief Financial Officer

    LEXINGTON, Mass., Sept. 12, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the promotion of Bill